260972-84-7Relevant academic research and scientific papers
LiBr-promoted photoredox neutral Minisci hydroxyalkylations of quinolines with aldehydes
Ji, Xiaochen,Liu, Qiong,Wang, Zhongzhen,Wang, Pu,Deng, Guo-Jun,Huang, Huawen
supporting information, p. 8233 - 8237 (2020/12/29)
Photoredox-neutral hydroxyalkylations of quinolines with aldehydes, induced by sustainable visible light under mild conditions, are described. Non-toxic and inexpensive LiBr is found to be the key for the success of the atom-economical Minisci method. Combined with a highly oxidative photocatalyst and visible light irradiation, the bromide additive mediates the H abstraction/acyl radical formation directly from aldehydes. The present mild photoredox neutral protocol provides an important alternative, especially for the challenging Minisci hydroalkylations, as well as a promising approach for atom-economical Minisci reactions with broader N-heterocycle spectra.
Development of quinoline-based disruptors of biofilm formation against Vibrio cholerae
León, Brian,Fong, Jiunn C. N.,Peach, Kelly C.,Wong, Weng Ruh,Yildiz, Fitnat H.,Linington, Roger G.
supporting information, p. 1234 - 1237 (2013/05/09)
Biofilm formation is a major cause of bacterial persistence in nosocomial infections, leading to extended treatment times and increased rates of morbidity and mortality. Despite this, there are currently no biofilm inhibitors approved for clinical use. Th
4-Quinolinemethanol derivatives as purine receptor antagonists (1)
-
, (2008/06/13)
Use a compound of formula (I) wherein: R1is hydrogen or alkyl; R2and R3are independently selected from hydrogen, alkyl, aryl and heterocyclyle or together may form a ring or R1and R2or R3together may form an oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1and R4to R9are hydrogen, R2or R3is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial. Said disorders are neurodegenerative disorders or movement disorders selected from Parkinson's disease or progressive supernuclear palsy, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.
